196 related articles for article (PubMed ID: 12087603)
21. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
Kaplan EM
Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
[TBL] [Abstract][Full Text] [Related]
22. Venlafaxine: a 2003 update.
Gutierrez MA; Stimmel GL; Aiso JY
Clin Ther; 2003 Aug; 25(8):2138-54. PubMed ID: 14512125
[TBL] [Abstract][Full Text] [Related]
23. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Benedict A; Arellano J; De Cock E; Baird J
J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
[TBL] [Abstract][Full Text] [Related]
25. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
Entsuah AR; Huang H; Thase ME
J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
[TBL] [Abstract][Full Text] [Related]
26. Venlafaxine and SSRI remission data revisited.
Kavirajan H
Br J Psychiatry; 2004 May; 184():452-3. PubMed ID: 15123513
[No Abstract] [Full Text] [Related]
27. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
[TBL] [Abstract][Full Text] [Related]
28. Managing depressive and anxiety disorders with escitalopram.
Thase ME
Expert Opin Pharmacother; 2006 Mar; 7(4):429-40. PubMed ID: 16503815
[TBL] [Abstract][Full Text] [Related]
29. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
Mallick R; Chen J; Entsuah AR; Schatzberg AF
J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
[TBL] [Abstract][Full Text] [Related]
30. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
Augustin BG; Cold JA; Jann MW
Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
[TBL] [Abstract][Full Text] [Related]
31. Venlafaxine augmentation with methylphenidate for treatment-refractory depression: a case report.
Bader GM; Hawley JM; Short DD
J Clin Psychopharmacol; 1998 Jun; 18(3):255-6. PubMed ID: 9617988
[No Abstract] [Full Text] [Related]
32. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
Smith D; Dempster C; Glanville J; Freemantle N; Anderson I
Br J Psychiatry; 2002 May; 180():396-404. PubMed ID: 11983635
[TBL] [Abstract][Full Text] [Related]
33. Venlafaxine versus sertraline for major depressive disorder.
Wise TN; Sheridan MJ
J Clin Psychiatry; 2000 Nov; 61(11):873-4. PubMed ID: 11105744
[No Abstract] [Full Text] [Related]
34. Drug therapy in treatment-resistant depression.
Malhi GS; Farmer AE
Br J Psychiatry; 1999 Oct; 175():390-1. PubMed ID: 10789311
[No Abstract] [Full Text] [Related]
35. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes.
Cantrell CR; Eaddy MT; Shah MB; Regan TS; Sokol MC
Med Care; 2006 Apr; 44(4):300-3. PubMed ID: 16565629
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
37. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders.
Stein MB; Cantrell CR; Sokol MC; Eaddy MT; Shah MB
Psychiatr Serv; 2006 May; 57(5):673-80. PubMed ID: 16675762
[TBL] [Abstract][Full Text] [Related]
38. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
Sheehan DV; Eaddy MT; Shah MB; Mauch RP
Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
Feighner JP; Entsuah AR; McPherson MK
J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
de Silva VA; Hanwella R
Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
